FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Anicetti Vincent R 2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [ CHRS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Operating Officer
(Last)         (First)         (Middle)
COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600
3. Date of Earliest Transaction (MM/DD/YYYY)
11/17/2020
(Street)
REDWOOD CITY, CA 94065
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/17/2020    M    2500  A $2.5005  51056 (1) D   
Common Stock  11/17/2020    S(2)    2500  D $17.4974 (3) 48556 (1) D   
Common Stock  11/17/2020    S    12420  D $17.6827 (4) 36136 (1) D   
Common Stock  11/17/2020    S    3567  D $17.677 (5) 32569 (1) D   
Common Stock  11/18/2020    M    4283  A $12.7  36852 (1) D   
Common Stock  11/18/2020    S(2)    4283  D $18.00  32569 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $2.5005  11/17/2020    M        2500    (6) 6/30/2024  Common Stock  2500  $0.00  7488  D   
Stock Option (Right to Buy)  $12.7  11/18/2020    M        4283    (6) 8/6/2027  Common Stock  4283  $0.00  22500  D   

Explanation of Responses:
(1)  Includes 31,250 restricted stock units.
(2)  The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
(3)  The transaction was executed in multiple trades in prices ranging from $17.27 to $17.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(4)  The transaction was executed in multiple trades in prices ranging from $17.44 to $17.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(5)  The transaction was executed in multiple trades in prices ranging from $17.46 to $17.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
(6)  All of the shares underlying this option are vested and exercisable as of the date hereof.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Anicetti Vincent R
COHERUS BIOSCIENCES, INC.
333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY, CA 94065


Chief Operating Officer

Signatures
/s/ Jean-Frederic Viret, as Attorney-in-Fact for Vincent R. Anicetti 11/19/2020
**Signature of Reporting Person Date
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Coherus BioSciences Charts.